Nanostring Cassettes and Associated Reagents

The Food and Drug Administration intends to award a sole source purchase order to Nanostring Technologies LLC to procure Nanostring cassettes and associated reagents through request for quote RFQ-FDA-2021-1241715. The cassettes provide the ability to simultaneously assay over 500 genes' expression for a single sample using twelve sample wells in each cassette, allowing multiple samples to be assessed at once. This proprietary technology from Nanostring Technologies provides a high-sensitivity, high-throughput technique to assess gene expression that would otherwise require significantly greater investment of time and money. Responses to demonstrate capability to meet this requirement are due by 12:00 p.m. EST on May 10, 2021 and should be emailed to Emmanuel Mbah.

No set-aside designation was used for this requirement. As the current owner of a Nanostring analysis instrument, the FDA requisition is for reagents to utilize the existing equipment, requiring no additional investment. An award is anticipated to Nanostring Technologies within approximately fifteen days following this notice unless another source is found capable. The proprietary nature of the technology and need for compatibility with current FDA equipment makes Nanostring Technologies the only known source.